Loading…

Waters CorporationWATCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of liquid chromatography and mass spectrometry instruments used for pharmaceutical quality control and scientific research.

Momentum leader 89
Mkt cap
$45.8B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$446M
20-day average traded
Fwd P/E
29.1×
forward earnings
ROIC−WACC
-8.2 pp
WACC 10.3%
Hurdle
+42 pp
Req g minus delivered
Next earnings
91 days
17 Feb 2027
Close · USD$466.10
1D+3.6%
1W-1.0%
1M+5.2%
3M+15.2%
6M+36.6%
YTD+22.7%
1Y+23.3%
ATR %3.1%
Beta0.96
52w lowhigh3.6% off high

What Waters does

Maker of liquid chromatography and mass spectrometry instruments used for pharmaceutical quality control and scientific research.

Sells chromatography instruments once, then earns recurring revenue from the columns, chemicals and service contracts needed to run them. Drugmakers' quality-control labs are the biggest buyers, and validated methods make them reluctant to switch instruments. It agreed in 2025 to combine with BD's biosciences and diagnostics business.

Products and services

  • Liquid chromatography (LC) systems
  • Mass spectrometry
  • TA Instruments (thermal/rheological analysis)

Customers

  • Pharma/biopharma QA/QC labs
  • Academic/government labs
  • Food/environmental testing labs

Where it sits in the supply chain

  • Healthcare/Life Sciences
  • Analytical instruments
  • Liquid chromatography & mass…

What could go right

  • Pharma QA/QC replacement cycle
  • Combination with BD's biosciences/diagnostics business

What could go wrong

  • Biopharma capex cycle sensitivity
  • China market softness

Moat: narrow (installed base, switching costs, brand). Long-established installed base in pharma QA/QC labs where chromatography methods are validated and hard to switch.

Headquarters: Milford, Massachusetts, USA · Founded: 1958 · Employees: 7,900

Named competitors

Waters at a glance

Size Waters (WAT) is a United States Health Care company (Medical Specialties) with a market value of $45.8B, the 271st largest of 3,085 United States companies the cockpit tracks. Shares closed at $466.10 on 18 Nov 2026.

Performance Over six months the shares gained 36.6%, against +26.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 80.7% over the last twelve months (peer median +8.4%); the operating margin is 9.5% (peer median 21.1%).

Valuation It trades at 29.1× forward earnings against a peer median of 27.2× (7th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 48% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.2 points below its cost of capital (10.3% WACC).

Backlog Backlog (remaining performance obligations) was $463M at 3 Oct 2026, up 54% on a year earlier — 0.1 years of trailing revenue. Backlog detail →

Short interest Short interest is 3.4% of the free float (30 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026WAT 137Peer median 122
Six months, rebased to 100: Waters against the median of its 20 peers (local-currency closes).

Waters financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.61B$3.17B$2.96B$2.96B$2.97B
Revenue growth—+7%0%-1%—
Gross profit$2.14B$1.83B$1.71B$1.73B$1.72B
EBITDA$1.40B$1.10B$1.04B$1.01B$1.02B
Net income$98.2M$643M$638M$642M$708M
Free cash flow$267M$516M$620M$442M$436M
Capital expenditure$189M$113M$142M$161M$183M
Total debt$5.50B$1.49B$1.70B$2.44B$1.66B

Quarterly statements and history in the cockpit →

Waters competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%+20%7741AMDLNSHLIDXXGEHCALCBDXEWMTDRMD300760BSXILMNDXCMWSTSTE4543ELWAT6-month return →1-month return →
Up and to the right = strong over both horizons. Waters is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%20×30×40×7741AMDLNSHLIDXXGEHCALCBDXEWMTDRMD300760BSXILMNWSTDIMWATRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Waters is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%+40%0%20%40%7741AMDLNSHLIDXXGEHCALCBDXMTDRMD300760BSXILMNDXCMSTEDIMELWATGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Waters is the large dot.

Waters competitors and peer comparison

Head to head with its named competitors (WAT vs A vs TMO vs 7701.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Waters WAT$45.8B+37%+81%10%29.1×48.1%
Agilent Technologies A$50.0B+56%+9%24%27.0×23.3%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Shimadzu 7701.T$8.14B+24%+8%14%21.0×8.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%

How Waters compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Waters against its 20 peers (data as of 18 Nov 2026)
MeasureWATPeer medianRank in peer set
1-month return+5.2%+7.3%8th lowest of 21
6-month return+36.6%+26.4%5th highest of 21
Distance from 52-week high-3.6%-8.3%6th highest of 21
Revenue growth (TTM)+80.7%+8.4%highest of 21
Operating margin9.5%21.1%2nd lowest of 21
Forward P/E29.1×27.2×7th most expensive of 21
Growth the price implies (Req g, 7 yrs)48.1%15.0%most demanding of 21
Growth delivered (Del g)+6.0%+9.4%6th lowest of 21
Hurdle (Req g minus delivered)+42.1 pp+3.9 ppmost demanding of 21
ROIC minus cost of capital-8.2 pp+3.9 pplowest of 21
EV / EBITDA36.3×19.1×most expensive of 20
Net debt / EBITDA3.5×1.1×most indebted of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%

Waters backlog

Waters reported $463M of remaining performance obligations at 3 Oct 2026, up 54% from a year earlier and down 6% from the previous quarter. That is 0.1 years of trailing revenue already under contract. Book-to-bill last quarter: 0.98.

Questions

Who are Waters's main competitors?
Named competitors: Agilent Technologies (A), Thermo Fisher Scientific (TMO), Shimadzu Corporation (7701.T), Danaher Corporation (DHR). The cockpit's measured peer set (industry) also includes Hoya (7741.T), Agilent Technologies (A), Medline (MDLN), Siemens Healthineers (SHL.DE), Idexx Laboratories (IDXX), GE HealthCare (GEHC).
Is Waters expensive compared with its peers?
On forward p/e it trades at 29.1× against a peer median of 27.2×, 7th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 48% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Waters stock performed?
Over six months to 18 Nov 2026 the shares returned +36.6% against +26.4% for the median peer; over one year +23.3%.
What is Waters's backlog?
Waters's remaining performance obligations (contracted revenue not yet recognised) were $463M at 3 Oct 2026, +54% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.